Stryker (NYSE:SYK) Given New $400.00 Price Target at Canaccord Genuity Group

Stryker (NYSE:SYK) had its target price cut by Canaccord Genuity Group from $435.00 to $400.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the medical technology company’s stock.

A number of other equities analysts have also commented on the stock. William Blair reiterated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. The Goldman Sachs Group dropped their target price on Stryker from $403.00 to $357.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Citigroup cut their price target on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Leerink Partners initiated coverage on Stryker in a report on Monday, April 13th. They issued an “outperform” rating and a $410.00 price target for the company. Finally, Evercore set a $355.00 price objective on Stryker in a research note on Friday. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $401.43.

Stryker Stock Down 6.3%

NYSE:SYK traded down $19.70 during trading hours on Friday, hitting $295.43. The stock had a trading volume of 4,518,113 shares, compared to its average volume of 1,836,681. The company has a market cap of $113.15 billion, a PE ratio of 35.17, a price-to-earnings-growth ratio of 1.84 and a beta of 0.92. The business has a 50 day simple moving average of $345.67 and a two-hundred day simple moving average of $356.95. Stryker has a 1-year low of $294.55 and a 1-year high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.74% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker will post 14.91 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Stryker’s payout ratio is 41.90%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.60% of the stock is owned by company insiders.

Institutional Trading of Stryker

Institutional investors and hedge funds have recently modified their holdings of the business. Brighton Jones LLC boosted its holdings in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new stake in Stryker during the second quarter worth about $205,000. Marshall Wace LLP lifted its holdings in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares during the last quarter. Nebula Research & Development LLC acquired a new position in Stryker in the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker in the second quarter valued at approximately $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.